BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 8854808)

  • 1. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.
    Farquharson AL; Pranesh N; Witham G; Swindell R; Taylor MB; Renehan AG; Rout S; Wilson MS; O'Dwyer ST; Saunders MP
    Br J Cancer; 2008 Aug; 99(4):591-6. PubMed ID: 18682713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomyxoma Peritonei: A Case Report Diagnosed in a 47-Year-Old Woman with Chronic Pelvic Abdominal Pain and Appendicular Origin: Review of the Literature and Management.
    Pugin F; Bouquet De Jolinière J; Major A; Khomsi F; Guillou L; Peter M; Ben Ali N; Egger B; Feki A
    Front Surg; 2017; 4():41. PubMed ID: 29326943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Treatment of Unresectable Pseudomyxoma Peritonei with Multiple Treatments of Intratumoural Bromelain and Acetylcysteine (BromAc
    Yang J; Glenn D; Lodh S; Valle S; Morris DL
    Case Rep Oncol; 2023; 16(1):1551-1556. PubMed ID: 38074518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Noguchi et al. Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei.
    Noguchi R; Yoshimatsu Y; Sin Y; Ono T; Tsuchiya R; Yoshida H; Kiyono T; Yonemura Y; Kondo T
    J Pers Med; 2023 Sep; 13(9):. PubMed ID: 37763192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASO Author Reflections: Pseudomyxoma Peritonei of Ovarian Origin-Modern Approach and Perspectives.
    Trecourt A; Bakrin N; Glehen O; Gertych W; Villeneuve L; Kepenekian V; Devouassoux-Shisheboran M;
    Ann Surg Oncol; 2024 Apr; 31(4):2755-2756. PubMed ID: 38200386
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pseudomyxoma peritonei: new concept and new therapeutic approach].
    Loungnarath R; Causeret S; Brigand C; Gilly FN; Glehen O
    Ann Chir; 2005 Feb; 130(2):63-9. PubMed ID: 15737316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intraperitoneal administration of a combined CDDP, 5-FU and MMC therapy for pseudomyxoma peritonei].
    Sasaki A; Terashima M; Okamoto K; Ikeda K; Takagane A; Takiyama I; Shimada Y; Yamamoto M; Nakajima J; Sasaki N; Saito K
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1828-31. PubMed ID: 10560405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
    Witkamp AJ; de Bree E; Kaag MM; van Slooten GW; van Coevorden F; Zoetmulder FA
    Br J Surg; 2001 Mar; 88(3):458-63. PubMed ID: 11260116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
    Sugarbaker PH
    Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment of pseudomyxoma peritonei using combination chemotherapy of intraperitoneal low-dose CDDP and oral 5'-DFUR administration].
    Ohta Y; Shima Y; Sasaki N; Nishida T; Yamayoshi T; Adachi A
    Gan To Kagaku Ryoho; 1998 May; 25(6):929-32. PubMed ID: 9617334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of pseudomyxoma peritonei of appendiceal origin--surgical resection and intraperitoneal chemotherapy.
    Hosch WP; Rudi J; Stremmel W
    Z Gastroenterol; 1999 Jul; 37(7):615-22. PubMed ID: 10458011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Two cases of pseudomyxoma peritonei that responded to intraperitoneal administrations of a combined CDDP, 5-FU and MMC therapy].
    Sasaki A; Terashima M; Okamoto K; Ikeda K; Takagane A; Takiyama I; Kuboi M; Sasaki N; Saito K
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1571-4. PubMed ID: 8854808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
    Sugarbaker PH
    Lancet Oncol; 2006 Jan; 7(1):69-76. PubMed ID: 16389186
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.